Table 5.
- Outcomes between patients with isoniazid-monoresistant and those with non-isoniazid resistance (n=105).
| Outcome | (n=9) | (n=96) | P-value |
|---|---|---|---|
| Duration of treatment (months) | Resistant | Nonresistant | |
| 1-6 | 0 | 15 (16.3) | 0.581 |
| 7-9 | 3 (3.3) | 32 (34.7) | |
| 10-12 | 2 (22.2) | 9 (9.2) | |
| >12 | 1 (11.1) | 7 (6.1) | |
| Loss to follow-up | 3 (33.3) | 33 (33.3) | |
| Mean x-bar (excluding loss to follow-up) | 12.00 | 9.46 | |
| Standard deviation | 6.033 | 3.711 | |
| Side effects | Resistant | Nonresistant | 0.079 |
| Drug-induced hepatitis | 1 (11.1) | 12 (12.2) | |
| Blurry vision | 1 (11.1) | 1 (1.02) | |
| Peripheral neuropathy | 1 (11.1) | 1 (1.02) | |
| Joint pain | 0 | 4 (4.1) | |
| No side effects | 6 (66.67) | 71 (72.5) | |
| Other side effects | 0 | 9 (9.2) | |
| Clinical outcome | Resistant | Nonresistant | |
| Successful treatment | 5 (55.56) | 51 (53.13) | 0.988 |
| Unsuccessful treatment | 1 (11.11) | 12 (12.5) | |
| → Relapse | 0 | 4 | |
| → Death | 1 | 8 | |
| Loss to follow-up | 3 (33.33) | 33 (34.38) | |
| Length of hospitalization (days) | Resistant | Nonresistant | |
| 1-25 | 1 | 43 | 0.130 |
| 26-50 | 2 | 20 | |
| >50 | 1 | 11 | |
| Unavailability | 5 | 22 | |
| Mean x-bar (excluding loss to follow-up) | 38.00 | 36.96 | |
| Standard deviation | 20.314 | 53.475 |
Values are presented as numbers and percentages (%).